Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir
about
Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionHepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizonProfile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infectionInterferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug ResistanceDosing Recommendations for Concomitant Medications During 3D Anti-HCV TherapyDrug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-RitonavirIntrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.Management of Post-Liver Transplant Recurrence of Hepatitis C.Clinical Pharmacokinetics of Ombitasvir.Clinical Pharmacokinetics of Paritaprevir.Clinical Pharmacokinetics of Dasabuvir.Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant UseTreatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney.Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus-Associated Membranoproliferative Glomerulonephritis.Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient.
P2860
Q26746563-9B3FB538-522E-4247-9986-E6B8ED484B91Q26773201-26AA19A6-753D-44E7-AE5C-226C1737AD27Q26775825-D65198BD-0E86-406F-A8AD-4BE5B04114DBQ26781331-96C91DB8-D681-463D-8ED8-299D201CAE54Q28080752-EAA3DEEC-5DAB-4519-BFFD-81A04C08BA25Q36438920-E3940627-5510-4028-9CD6-8088D07FDFA5Q38750141-5083A1B3-8965-40E0-A597-F3F4CD6A485BQ38929010-8DE17297-01DB-4549-9254-3327164AD2D4Q39017681-7D862C0A-AD3F-42D2-B6DF-4F21D264D845Q39147495-30BF6880-0095-432C-86B8-6D691223DB2FQ39150134-5CC80401-78AD-41F6-AA2C-666F57694887Q39160612-5F556275-2649-4B3C-A8B2-CFCFAC0E521DQ39478255-FA69FC4D-7F35-41C0-9CFD-4DF1EE8DEDC4Q40705980-14DAF8C5-1F08-49D5-8EE1-68BFB19B1D93Q45325791-47828663-4F8C-4E63-B546-CA9CBCF86A59Q45332478-92F01724-4A47-4284-AFB2-3265AFB2FD3EQ54767891-C5613EDB-2168-445D-801D-87676887DC5A
P2860
Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 February 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and dose reco ...... 450, ombitasvir, and dasabuvir
@en
Pharmacokinetics and dose reco ...... 50, ombitasvir, and dasabuvir.
@nl
type
label
Pharmacokinetics and dose reco ...... 450, ombitasvir, and dasabuvir
@en
Pharmacokinetics and dose reco ...... 50, ombitasvir, and dasabuvir.
@nl
prefLabel
Pharmacokinetics and dose reco ...... 450, ombitasvir, and dasabuvir
@en
Pharmacokinetics and dose reco ...... 50, ombitasvir, and dasabuvir.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and dose reco ...... 450, ombitasvir, and dasabuvir
@en
P2093
B Bernstein
T Podsadecki
P2860
P304
P356
10.1111/AJT.13111
P407
P577
2015-02-23T00:00:00Z